Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
ConclusionsIn Asian subjects with DPNP, mirogabalin (5, 10, and 15 mg BID) was well tolerated. Although no significant differences were observed in the primary endpoint, there was a tendency toward improvement of pain with mirogabalin treatment, and this trend was also observed in the secondary endpoints.Trial RegistrationClinicalTrials.gov identifier, NCT01504412.
Source: Pain and Therapy - Category: Anesthesiology Source Type: research
More News: Anesthesiology | Brain | Diabetes | Endocrinology | Insomnia | Japan Health | Lyrica | Neurology | Pain | Sleep Disorders | Sleep Medicine | South Korea Health | Statistics | Study | Taiwan Health